The risk of having prostate cancer is currently assessed by the triad of elevated serum prostate specific antigen (PSA; typically ≥3 ng/mL), abnormal digital rectal examination (DRE), and transrectal ultrasonography (TRUS) [21]. This evidence concerns the gene KLK3 and prostate cancer.